Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Кто или что влияет на оптимальный выбор пути введения лекарственных средств – это решение клинициста, пациента или государства?
Кто или что влияет на оптимальный выбор пути введения лекарственных средств – это решение клинициста, пациента или государства?
Колбин А.С., Гомон Ю.М., Хохлова С.В. Кто или что влияет на оптимальный выбор пути введения лекарственных средств – это решение клинициста, пациента или государства? Новые и, казалось бы, неожиданные вопросы для российского здравоохранения. Современная Онкология. 2016; 18 (3): 12–18.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
За последнее десятилетие в лекарственном лечении хронических заболеваний появились новые возможности, которые включают разный выбор режимов терапии, а также места ее проведения (амбулаторно, на дому, в стационаре). Информированность пациента о наличии альтернативных возможностей – важный фактор успешности терапии в плане ее приверженности пациентами и сохранения их качества жизни. Целью данного исследования явилось изучение факторов, влияющих на выбор пути введения лекарств, используемых при различных нозологиях. С этой целью в базе данных PubMed проведен анализ всех публикаций в период с 1990 по 2016 г., посвященных вопросам сравнения эффективности, безопасности, фармако-экономики, предпочтений пациентов при разных путях введения одного и того же лекарства. В результате анализа литературы был бесспорно доказан тот факт, что основными критериями выбора лекарств являются эффективность, безопасность, фармакоэкономические аспекты, а также предпочтения пациента. При этом последнее – важный фактор в достижении высокой приверженности терапии, повышении показателей эффективности медицинской технологии и улучшения качества жизни пациентов.
Ключевые слова: путь введения, эффективность, безопасность, предпочтения пациентов.
Key words: administration route, efficiency, safety, patient preference.
Ключевые слова: путь введения, эффективность, безопасность, предпочтения пациентов.
________________________________________________
Key words: administration route, efficiency, safety, patient preference.
Полный текст
Список литературы
1. https://rg.ru/2011/11/23/zdorovie-dok.html
2. Stoner KL, Harder H, Fallowfield LJ et al. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review. Patient 2015; 8: 145–53.
3. Постановление Правительства РФ от 28 октября 2015 г. №1154 «О порядке определения взаимозаменяемости лекарственных препаратов для медицинского применения». www.rlsnet.ru/Files/na/1154.pdf / Postanovlenie Pravitel'stva RF ot 28 oktiabria 2015 g. № 1154 "O poriadke opredeleniia vzaimozameniaemosti lekarstvennykh preparatov dlia meditsinskogo primeneniia". www.rlsnet.ru/Files/na/1154.pdf / [in Russian]
4. Приказ ФАС России от 28.04.2010 N 220 (ред. от 23.11.2015) "Об утверждении Порядка проведения анализа состояния конкуренции на товарном рынке". http://www.consultant.ru/document/cons_doc_ LAW_103446/ / Prikaz FAS Rossii ot 28.04.2010 N 220 (red. ot 23.11.2015) "Ob utverzhdenii Poriadka provedeniia analiza sostoianiia konkurentsii na tovarnom rynke". http:// www.consultant.ru/document/cons_doc_LAW_ 103446/ [in Russian]
5. Федеральный Закон №135 "О защите конкуренции» от 26.07.2006 в редакции от 04.07.2016. http://www.consultant.ru/ document/cons_doc_ LAW_61763/ / Federal'nyi Zakon №135 «O zashchite konkurentsii" ot 26.07.2006 v redaktsii ot 04.07.2016. http://www.consultant.ru/document/ cons_doc_LAW_61763 [in Russian]
6. Jin J et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient preference and adherence 2015: 9; 923–42.
7. Кукес В.Г. Клиническая фармакология. М: ГЭОТАР-Медиа, 2015. / Kukes V.G. Klinicheskaia farmakologiia. M: GEOTAR-Media, 2015. [in Russian]
8. Arthur J, Atkinson Jr, Darrell R. Abernethy etc. Principles of Clinical Pharmacology; Academic Press, 2006.
9. Основные понятия в оценке медицинских технологий: метод. пособие. Под ред. Колбина А.С., Зырянова С.К., Белоусова Д.Ю. М.: Издательство ОКИ, 2013. / Osnovnye poniatiia v otsenke meditsinskikh tekhnologii: metod. posobie. Pod red. Kolbina A.S., Zyrianova S.K., Belousova D.Iu. M.: Izdatel'stvo OKI, 2013. [in Russian]
10. PaPadmitriou K et al. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts Views Vis Obgyn 2015; 7 (3): 176–80.
11. Ismael G et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncology. 2012; 13 (9): 869–78.
12. Jackisch C et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncolog 2015; 26; 320–5.
13. Lui J et al. Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn’s Disease: A Comparison of Effectiveness and Safety. J Manag Care Spec Pharm 2015; 21 (7): 559–66.
14. Mystakidou K et al. Oral versus intravenous ibandronic acid: a comparison for metastatic bone disease. J Cancer Res Clin Oncol 2008; 134 (12); 1303–10.
15. Pivot X, Gligorov J, Müller V et al. Pref Her Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenousinfusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol 2014; 25 (10): 1979–87.
16. http://www.rlsnet.ru/tn_index_id_2581.htm
17. http://www.rlsnet.ru/tn_index_id_4539.htm
18. Shah DK, Missmer SA, Correia KF et al. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. J Clin Endocrinol Metab 2014; 99 (4): 1314–21.
19. Nisbet AC. Intramuscular gluteal injections in the increasingly obese population: retrospective study. BMJ 2006; 332 (7542): 637–8.
20. Zaybak A, Gunes UY, Tamsel S et al. Does obesity prevent the needle from reaching muscle in intramuscular injections? J Adv Nurs 2007; 58 (6): 552–6.
21. WHO Library Cataloguing-in-Publication Data: WHO model formulary for children 2010. Based on the second model list of essential medicines for children 2009.
22. Miller A, Hancock F. Sequential therapy for significant infection: a comparison of the efficacy, safety profile and cost of intravenous cefuroxime followed by oral cefuroxime axetil versus cefotaxime. In: Abstracts of the 7th ECCMID, Vienna, Austria, 1995, 128.
23. Sylwestrzak G et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. American Health Drug Benefits 2014; 7 (2): 71–81.
24. Lewiecki EM et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month open-label, prospective evaluation. Clin Ther 2008; 30 (4): 605–21.
25. Zhang J et al. Trends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare Program. Arthritis Care Res 2013;
65 (11): 1743–51.
26. Kamimura T, Miyamoto T, Yokota N et al. High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib. Int J Hematol 2013; 98 (6): 694–701.
27. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108 (5): 871–3.
28. Kagan L, Turner MR, Balu-Iyer SV et al. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 2012; 29 (2): 490–9.
29. Weiss LG et al. The efficacy of once weekly compared with 2 or 3 times weekly subcutaneous epoetin-β: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014–9.
30. Wasserman RL, Melamed I, Stein MR et al; IGSC, 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130 (4): 951–7.e11.
31. Pezzarossa A, Taddei F, Cimicchi MC et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 1988; 11 (1): 52–8.
32. http://www.rlsnet.ru/tn_index_id_5689.htm
33. http://www.rlsnet.ru/tn_index_id_3026.htm
34. Рачина С.А. и др. Анализ антибактериальной терапии госпитализированных пациентов с внебольничной пневмонией в различных регионах РФ: уроки многоцентрового фармакоэпидемиологического исследования. Клин. фармакология и антимикроб. химиотерапия. 2009; 11 (1): 66–78. / Rachina S.A. i dr. Analiz antibakterial'noi terapii gospitalizirovannykh patsientov s vnebol'nichnoi pnevmoniei v razlichnykh regionakh RF: uroki mnogotsentrovogo farmakoepidemiologicheskogo issledovaniia. Klin. farmakologiia i antimikrob. khimioterapiia. 2009; 11 (1): 66–78. [in Russian]
35. De Cock E et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Medicine 2016; 5 (3): 389–97.
36. De Cock E et al. Time Savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One 2016; 11 (6): e0157957.
37. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533–43.
38. Pharmaceutical Care – Policies and Practices for a Safer, More Responsible and Cost-effective Health System is published by the Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM). Ed. Dr S. Keitel Page layout and cover: EDQM European Directorate for the Quality of Medicines & HealthCare (EDQM). Printed on acid-free paper at the Council of Europe. 62 р.
39. Willeke P et al. Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis. Z Rheumatol 2011; 70 (3): 232–4.
40. Greenapple R. Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers. Am Health Drug Benefits 2012; 5 (2): 83–92.
2. Stoner KL, Harder H, Fallowfield LJ et al. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review. Patient 2015; 8: 145–53.
3. Postanovlenie Pravitel'stva RF ot 28 oktiabria 2015 g. № 1154 "O poriadke opredeleniia vzaimozameniaemosti lekarstvennykh preparatov dlia meditsinskogo primeneniia". www.rlsnet.ru/Files/na/1154.pdf / [in Russian]
4. Prikaz FAS Rossii ot 28.04.2010 N 220 (red. ot 23.11.2015) "Ob utverzhdenii Poriadka provedeniia analiza sostoianiia konkurentsii na tovarnom rynke". http:// www.consultant.ru/document/cons_doc_LAW_ 103446/ [in Russian]
5. Federal'nyi Zakon №135 «O zashchite konkurentsii" ot 26.07.2006 v redaktsii ot 04.07.2016. http://www.consultant.ru/document/ cons_doc_LAW_61763 [in Russian]
6. Jin J et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient preference and adherence 2015: 9; 923–42.
7. Kukes V.G. Klinicheskaia farmakologiia. M: GEOTAR-Media, 2015. [in Russian]
8. Arthur J, Atkinson Jr, Darrell R. Abernethy etc. Principles of Clinical Pharmacology; Academic Press, 2006.
9. Osnovnye poniatiia v otsenke meditsinskikh tekhnologii: metod. posobie. Pod red. Kolbina A.S., Zyrianova S.K., Belousova D.Iu. M.: Izdatel'stvo OKI, 2013. [in Russian]
10. PaPadmitriou K et al. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts Views Vis Obgyn 2015; 7 (3): 176–80.
11. Ismael G et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncology. 2012; 13 (9): 869–78.
12. Jackisch C et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncolog 2015; 26; 320–5.
13. Lui J et al. Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn’s Disease: A Comparison of Effectiveness and Safety. J Manag Care Spec Pharm 2015; 21 (7): 559–66.
14. Mystakidou K et al. Oral versus intravenous ibandronic acid: a comparison for metastatic bone disease. J Cancer Res Clin Oncol 2008; 134 (12); 1303–10.
15. Pivot X, Gligorov J, Müller V et al. Pref Her Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenousinfusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol 2014; 25 (10): 1979–87.
16. http://www.rlsnet.ru/tn_index_id_2581.htm
17. http://www.rlsnet.ru/tn_index_id_4539.htm
18. Shah DK, Missmer SA, Correia KF et al. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. J Clin Endocrinol Metab 2014; 99 (4): 1314–21.
19. Nisbet AC. Intramuscular gluteal injections in the increasingly obese population: retrospective study. BMJ 2006; 332 (7542): 637–8.
20. Zaybak A, Gunes UY, Tamsel S et al. Does obesity prevent the needle from reaching muscle in intramuscular injections? J Adv Nurs 2007; 58 (6): 552–6.
21. WHO Library Cataloguing-in-Publication Data: WHO model formulary for children 2010. Based on the second model list of essential medicines for children 2009.
22. Miller A, Hancock F. Sequential therapy for significant infection: a comparison of the efficacy, safety profile and cost of intravenous cefuroxime followed by oral cefuroxime axetil versus cefotaxime. In: Abstracts of the 7th ECCMID, Vienna, Austria, 1995, 128.
23. Sylwestrzak G et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. American Health Drug Benefits 2014; 7 (2): 71–81.
24. Lewiecki EM et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month open-label, prospective evaluation. Clin Ther 2008; 30 (4): 605–21.
25. Zhang J et al. Trends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare Program. Arthritis Care Res 2013;
65 (11): 1743–51.
26. Kamimura T, Miyamoto T, Yokota N et al. High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib. Int J Hematol 2013; 98 (6): 694–701.
27. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108 (5): 871–3.
28. Kagan L, Turner MR, Balu-Iyer SV et al. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 2012; 29 (2): 490–9.
29. Weiss LG et al. The efficacy of once weekly compared with 2 or 3 times weekly subcutaneous epoetin-β: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014–9.
30. Wasserman RL, Melamed I, Stein MR et al; IGSC, 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130 (4): 951–7.e11.
31. Pezzarossa A, Taddei F, Cimicchi MC et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 1988; 11 (1): 52–8.
32. http://www.rlsnet.ru/tn_index_id_5689.htm
33. http://www.rlsnet.ru/tn_index_id_3026.htm
34. Rachina S.A. i dr. Analiz antibakterial'noi terapii gospitalizirovannykh patsientov s vnebol'nichnoi pnevmoniei v razlichnykh regionakh RF: uroki mnogotsentrovogo farmakoepidemiologicheskogo issledovaniia. Klin. farmakologiia i antimikrob. khimioterapiia. 2009; 11 (1): 66–78. [in Russian]
35. De Cock E et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Medicine 2016; 5 (3): 389–97.
36. De Cock E et al. Time Savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One 2016; 11 (6): e0157957.
37. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533–43.
38. Pharmaceutical Care – Policies and Practices for a Safer, More Responsible and Cost-effective Health System is published by the Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM). Ed. Dr S. Keitel Page layout and cover: EDQM European Directorate for the Quality of Medicines & HealthCare (EDQM). Printed on acid-free paper at the Council of Europe. 62 р.
39. Willeke P et al. Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis. Z Rheumatol 2011; 70 (3): 232–4.
40. Greenapple R. Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers. Am Health Drug Benefits 2012; 5 (2): 83–92.
2. Stoner KL, Harder H, Fallowfield LJ et al. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review. Patient 2015; 8: 145–53.
3. Постановление Правительства РФ от 28 октября 2015 г. №1154 «О порядке определения взаимозаменяемости лекарственных препаратов для медицинского применения». www.rlsnet.ru/Files/na/1154.pdf / Postanovlenie Pravitel'stva RF ot 28 oktiabria 2015 g. № 1154 "O poriadke opredeleniia vzaimozameniaemosti lekarstvennykh preparatov dlia meditsinskogo primeneniia". www.rlsnet.ru/Files/na/1154.pdf / [in Russian]
4. Приказ ФАС России от 28.04.2010 N 220 (ред. от 23.11.2015) "Об утверждении Порядка проведения анализа состояния конкуренции на товарном рынке". http://www.consultant.ru/document/cons_doc_ LAW_103446/ / Prikaz FAS Rossii ot 28.04.2010 N 220 (red. ot 23.11.2015) "Ob utverzhdenii Poriadka provedeniia analiza sostoianiia konkurentsii na tovarnom rynke". http:// www.consultant.ru/document/cons_doc_LAW_ 103446/ [in Russian]
5. Федеральный Закон №135 "О защите конкуренции» от 26.07.2006 в редакции от 04.07.2016. http://www.consultant.ru/ document/cons_doc_ LAW_61763/ / Federal'nyi Zakon №135 «O zashchite konkurentsii" ot 26.07.2006 v redaktsii ot 04.07.2016. http://www.consultant.ru/document/ cons_doc_LAW_61763 [in Russian]
6. Jin J et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient preference and adherence 2015: 9; 923–42.
7. Кукес В.Г. Клиническая фармакология. М: ГЭОТАР-Медиа, 2015. / Kukes V.G. Klinicheskaia farmakologiia. M: GEOTAR-Media, 2015. [in Russian]
8. Arthur J, Atkinson Jr, Darrell R. Abernethy etc. Principles of Clinical Pharmacology; Academic Press, 2006.
9. Основные понятия в оценке медицинских технологий: метод. пособие. Под ред. Колбина А.С., Зырянова С.К., Белоусова Д.Ю. М.: Издательство ОКИ, 2013. / Osnovnye poniatiia v otsenke meditsinskikh tekhnologii: metod. posobie. Pod red. Kolbina A.S., Zyrianova S.K., Belousova D.Iu. M.: Izdatel'stvo OKI, 2013. [in Russian]
10. PaPadmitriou K et al. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts Views Vis Obgyn 2015; 7 (3): 176–80.
11. Ismael G et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncology. 2012; 13 (9): 869–78.
12. Jackisch C et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncolog 2015; 26; 320–5.
13. Lui J et al. Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn’s Disease: A Comparison of Effectiveness and Safety. J Manag Care Spec Pharm 2015; 21 (7): 559–66.
14. Mystakidou K et al. Oral versus intravenous ibandronic acid: a comparison for metastatic bone disease. J Cancer Res Clin Oncol 2008; 134 (12); 1303–10.
15. Pivot X, Gligorov J, Müller V et al. Pref Her Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenousinfusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol 2014; 25 (10): 1979–87.
16. http://www.rlsnet.ru/tn_index_id_2581.htm
17. http://www.rlsnet.ru/tn_index_id_4539.htm
18. Shah DK, Missmer SA, Correia KF et al. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. J Clin Endocrinol Metab 2014; 99 (4): 1314–21.
19. Nisbet AC. Intramuscular gluteal injections in the increasingly obese population: retrospective study. BMJ 2006; 332 (7542): 637–8.
20. Zaybak A, Gunes UY, Tamsel S et al. Does obesity prevent the needle from reaching muscle in intramuscular injections? J Adv Nurs 2007; 58 (6): 552–6.
21. WHO Library Cataloguing-in-Publication Data: WHO model formulary for children 2010. Based on the second model list of essential medicines for children 2009.
22. Miller A, Hancock F. Sequential therapy for significant infection: a comparison of the efficacy, safety profile and cost of intravenous cefuroxime followed by oral cefuroxime axetil versus cefotaxime. In: Abstracts of the 7th ECCMID, Vienna, Austria, 1995, 128.
23. Sylwestrzak G et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. American Health Drug Benefits 2014; 7 (2): 71–81.
24. Lewiecki EM et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month open-label, prospective evaluation. Clin Ther 2008; 30 (4): 605–21.
25. Zhang J et al. Trends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare Program. Arthritis Care Res 2013;
65 (11): 1743–51.
26. Kamimura T, Miyamoto T, Yokota N et al. High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib. Int J Hematol 2013; 98 (6): 694–701.
27. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108 (5): 871–3.
28. Kagan L, Turner MR, Balu-Iyer SV et al. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 2012; 29 (2): 490–9.
29. Weiss LG et al. The efficacy of once weekly compared with 2 or 3 times weekly subcutaneous epoetin-β: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014–9.
30. Wasserman RL, Melamed I, Stein MR et al; IGSC, 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130 (4): 951–7.e11.
31. Pezzarossa A, Taddei F, Cimicchi MC et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 1988; 11 (1): 52–8.
32. http://www.rlsnet.ru/tn_index_id_5689.htm
33. http://www.rlsnet.ru/tn_index_id_3026.htm
34. Рачина С.А. и др. Анализ антибактериальной терапии госпитализированных пациентов с внебольничной пневмонией в различных регионах РФ: уроки многоцентрового фармакоэпидемиологического исследования. Клин. фармакология и антимикроб. химиотерапия. 2009; 11 (1): 66–78. / Rachina S.A. i dr. Analiz antibakterial'noi terapii gospitalizirovannykh patsientov s vnebol'nichnoi pnevmoniei v razlichnykh regionakh RF: uroki mnogotsentrovogo farmakoepidemiologicheskogo issledovaniia. Klin. farmakologiia i antimikrob. khimioterapiia. 2009; 11 (1): 66–78. [in Russian]
35. De Cock E et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Medicine 2016; 5 (3): 389–97.
36. De Cock E et al. Time Savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One 2016; 11 (6): e0157957.
37. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533–43.
38. Pharmaceutical Care – Policies and Practices for a Safer, More Responsible and Cost-effective Health System is published by the Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM). Ed. Dr S. Keitel Page layout and cover: EDQM European Directorate for the Quality of Medicines & HealthCare (EDQM). Printed on acid-free paper at the Council of Europe. 62 р.
39. Willeke P et al. Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis. Z Rheumatol 2011; 70 (3): 232–4.
40. Greenapple R. Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers. Am Health Drug Benefits 2012; 5 (2): 83–92.
________________________________________________
2. Stoner KL, Harder H, Fallowfield LJ et al. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review. Patient 2015; 8: 145–53.
3. Postanovlenie Pravitel'stva RF ot 28 oktiabria 2015 g. № 1154 "O poriadke opredeleniia vzaimozameniaemosti lekarstvennykh preparatov dlia meditsinskogo primeneniia". www.rlsnet.ru/Files/na/1154.pdf / [in Russian]
4. Prikaz FAS Rossii ot 28.04.2010 N 220 (red. ot 23.11.2015) "Ob utverzhdenii Poriadka provedeniia analiza sostoianiia konkurentsii na tovarnom rynke". http:// www.consultant.ru/document/cons_doc_LAW_ 103446/ [in Russian]
5. Federal'nyi Zakon №135 «O zashchite konkurentsii" ot 26.07.2006 v redaktsii ot 04.07.2016. http://www.consultant.ru/document/ cons_doc_LAW_61763 [in Russian]
6. Jin J et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient preference and adherence 2015: 9; 923–42.
7. Kukes V.G. Klinicheskaia farmakologiia. M: GEOTAR-Media, 2015. [in Russian]
8. Arthur J, Atkinson Jr, Darrell R. Abernethy etc. Principles of Clinical Pharmacology; Academic Press, 2006.
9. Osnovnye poniatiia v otsenke meditsinskikh tekhnologii: metod. posobie. Pod red. Kolbina A.S., Zyrianova S.K., Belousova D.Iu. M.: Izdatel'stvo OKI, 2013. [in Russian]
10. PaPadmitriou K et al. The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives. Facts Views Vis Obgyn 2015; 7 (3): 176–80.
11. Ismael G et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncology. 2012; 13 (9): 869–78.
12. Jackisch C et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncolog 2015; 26; 320–5.
13. Lui J et al. Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn’s Disease: A Comparison of Effectiveness and Safety. J Manag Care Spec Pharm 2015; 21 (7): 559–66.
14. Mystakidou K et al. Oral versus intravenous ibandronic acid: a comparison for metastatic bone disease. J Cancer Res Clin Oncol 2008; 134 (12); 1303–10.
15. Pivot X, Gligorov J, Müller V et al. Pref Her Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenousinfusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol 2014; 25 (10): 1979–87.
16. http://www.rlsnet.ru/tn_index_id_2581.htm
17. http://www.rlsnet.ru/tn_index_id_4539.htm
18. Shah DK, Missmer SA, Correia KF et al. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. J Clin Endocrinol Metab 2014; 99 (4): 1314–21.
19. Nisbet AC. Intramuscular gluteal injections in the increasingly obese population: retrospective study. BMJ 2006; 332 (7542): 637–8.
20. Zaybak A, Gunes UY, Tamsel S et al. Does obesity prevent the needle from reaching muscle in intramuscular injections? J Adv Nurs 2007; 58 (6): 552–6.
21. WHO Library Cataloguing-in-Publication Data: WHO model formulary for children 2010. Based on the second model list of essential medicines for children 2009.
22. Miller A, Hancock F. Sequential therapy for significant infection: a comparison of the efficacy, safety profile and cost of intravenous cefuroxime followed by oral cefuroxime axetil versus cefotaxime. In: Abstracts of the 7th ECCMID, Vienna, Austria, 1995, 128.
23. Sylwestrzak G et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. American Health Drug Benefits 2014; 7 (2): 71–81.
24. Lewiecki EM et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month open-label, prospective evaluation. Clin Ther 2008; 30 (4): 605–21.
25. Zhang J et al. Trends in the Use of Biologic Agents Among Rheumatoid Arthritis Patients Enrolled in the US Medicare Program. Arthritis Care Res 2013;
65 (11): 1743–51.
26. Kamimura T, Miyamoto T, Yokota N et al. High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib. Int J Hematol 2013; 98 (6): 694–701.
27. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108 (5): 871–3.
28. Kagan L, Turner MR, Balu-Iyer SV et al. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 2012; 29 (2): 490–9.
29. Weiss LG et al. The efficacy of once weekly compared with 2 or 3 times weekly subcutaneous epoetin-β: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014–9.
30. Wasserman RL, Melamed I, Stein MR et al; IGSC, 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012; 130 (4): 951–7.e11.
31. Pezzarossa A, Taddei F, Cimicchi MC et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care 1988; 11 (1): 52–8.
32. http://www.rlsnet.ru/tn_index_id_5689.htm
33. http://www.rlsnet.ru/tn_index_id_3026.htm
34. Rachina S.A. i dr. Analiz antibakterial'noi terapii gospitalizirovannykh patsientov s vnebol'nichnoi pnevmoniei v razlichnykh regionakh RF: uroki mnogotsentrovogo farmakoepidemiologicheskogo issledovaniia. Klin. farmakologiia i antimikrob. khimioterapiia. 2009; 11 (1): 66–78. [in Russian]
35. De Cock E et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Medicine 2016; 5 (3): 389–97.
36. De Cock E et al. Time Savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One 2016; 11 (6): e0157957.
37. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533–43.
38. Pharmaceutical Care – Policies and Practices for a Safer, More Responsible and Cost-effective Health System is published by the Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM). Ed. Dr S. Keitel Page layout and cover: EDQM European Directorate for the Quality of Medicines & HealthCare (EDQM). Printed on acid-free paper at the Council of Europe. 62 р.
39. Willeke P et al. Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis. Z Rheumatol 2011; 70 (3): 232–4.
40. Greenapple R. Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers. Am Health Drug Benefits 2012; 5 (2): 83–92.
Авторы
А.С.Колбин*1,2, Ю.М.Гомон1, С.В.Хохлова3
1 ФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет им. И.П.Павлова Минздрава России. 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8;
2 ФГБОУ ВПО Санкт-Петербургский государственный университет. 199034, Санкт-Петербург, Университетская наб. д. 7/9;
3 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*аlex.kolbin@mail.ru
1 I.M.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation. 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8;
2 Saint Petersburg State University. 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9;
3 N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*аlex.kolbin@mail.ru
1 ФГБОУ ВО Первый Санкт-Петербургский государственный медицинский университет им. И.П.Павлова Минздрава России. 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8;
2 ФГБОУ ВПО Санкт-Петербургский государственный университет. 199034, Санкт-Петербург, Университетская наб. д. 7/9;
3 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23
*аlex.kolbin@mail.ru
________________________________________________
1 I.M.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation. 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8;
2 Saint Petersburg State University. 199034, Russian Federation, Saint Petersburg, Universitetskaia nab., d. 7/9;
3 N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
*аlex.kolbin@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.